¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"hepatitis b surface antigens"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • halothane hepatitis
    ÇÒ·Îź°£¿°
  • infantile hepatitis
    ¿µ¾Æ°£¿°
  • infectious hepatitis
    Àü¿°¼º°£¿°
  • lupus hepatitis
    ·çǪ½º°£¿°
  • neonatal hepatitis
    ½Å»ý¾Æ°£¿°
  • non-A, non-B hepatitis
    ABÀ̿ܰ£¿°, ºñA, ºñB°£¿°
  • post-transfusion hepatitis
    ¼öÇ÷Èİ£¿°
  • suppurative hepatitis
    È­³ó°£¿°
  • serum hepatitis
    Ç÷û°£¿°
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type A
    AÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type B
    BÇü¹ÙÀÌ·¯½º°£¿°
  • viral hepatitis type D
    DÇü¹ÙÀÌ·¯½º°£¿°
  • approximal surface
    Á¢Ã˸é, ÀÎÁ¢¸é
  • articular surface
    °üÀý¸é
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • post-transfusion hepatitis
    ¼öÇ÷Èİ£¿°
  • serum hepatitis
    Ç÷û°£¿°
  • suppurative hepatitis
    È­³ó°£¿°
  • toxic hepatitis
    µ¶¼º°£¿°
  • toxipathic hepatitis
    µ¶¹°¼º°£¿°
  • transfusion hepatitis
    (¢¡post-transfusion hepatitis) ¼öÇ÷Èİ£¿°
  • viral hepatitis
    ¹ÙÀÌ·¯½º°£¿°
  • anterolateral surface
    ¾Õ°¡Âʸé
  • anteromedial surface
    ¾Õ¾ÈÂʸé
  • approximal surface
    Á¢Ã˸é
  • articular surface
    °üÀý¸é
  • surface anesthesia
    Ç¥¸é¸¶Ãë
  • surface antigen
    Ç¥¸éÇ׿ø
  • surface area
    üǥ¸éÀû, Ç¥¸éÀû
  • surface refrigeration anesthesia
    Ç¥¸é³Ãµ¿¸¶Ãë
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • articular surface of head of rib
    °¥ºñ»À¸Ó¸®°üÀý¸é
  • articular surface of tubercle
    °¥ºñ»À°áÀý°üÀý¸é
  • gastric surface
    À§¸é
  • glenoid surface
    °üÀý¿Í¸é(μï½èÀØü).
  • glenoid surface
    °üÀý¿Í ¸é(μï½èÀØü).
  • gluteal surface
    µÐºÎ±Ù¸é, µÐ±Ù¸é(ÔëÐÉØü).
  • gluteal surface
    º¼±â±Ù¸é
  • gluteal surface
    µÐ ¸é, µÐºÎ±Ù ¸é, µÐ±Ù ¸é(ÔëÐÉØü).
  • immunoglobulin, surface
    ¼¼Æ÷Ç¥¸é ¸é¿ª±Û·ÎºÒ¸°
  • impression of root surface
    ±Ù¸éÀλó(ÐÆØü ìÔßÚ).
  • incisal surface
    Àý´Ü¸é(ôîÓ®Øü).
  • inferior articular surface
    ¾Æ·¡°üÀý¸é
  • inferior surface
    ¾Æ·¡¸é
  • inferior surface of petrous portion
    ¹ÙÀ§¾Æ·¡¸é
  • inferior surface of tongue
    Çô¾Æ·¡¸é
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • delta hepatitis.
    d Çü °£¿°, µ¨Å¸°£¿°
  • drug-induced hepatitis
    ¾à¹°¼º °£¿°(¡­°£¿°).
  • drug-induced hepatitis
    ¾à¹° [¼ÒÈ­]¾à¹°¼º °£¿°(¡­ÊÜæú).
  • drug-induced hepatitis
    ¾à¹° ¼ÒÈ­¾à¹°¼º °£¿°(¡­ÊÜæú).
  • epidemic hepatitis
    À¯Ç༺ °£¿°.
  • epizootic hepatitis
    µ¿¹°À¯Ç༺ °£¿°.
  • fulminant hepatitis
    Àü°Ý¼º °£¿°
  • fulminant hepatitis
    Àü°Ý¼º °£¿°.
  • fulminant hepatitis
    Àü°Ý¼º°£¿°(¡­ÊÜæú)
  • fulminating hepatitis
    Àü°Ý¼º °£¿°.
  • granulomatous hepatitis
    À°¾ÆÁ¾¼º °£¿°.
  • gummatous hepatitis
    °í¹«Á¾¼º °£¿°.
  • hemorrhagic hepatitis
    ÃâÇ÷(¼º) °£¿°.
  • hepatitis
    °£¿°(ÊÜæú).
  • hepatitis A virus(HAV)
    AÇü °£¿°¹ÙÀÌ·¯½º
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Distal surface
    ¸ÕÂʸé
    [¿¾ ¿ë¾î] ¿ø½É¸é
  • Arytenoid articular surface
    ¸ð»Ô°üÀý¸é
    [¿¾ ¿ë¾î] ÇÇ¿­°üÀý¸é
  • Intervertebral surface
    ¸öÅë»çÀ̸é
    [¿¾ ¿ë¾î] Ãß°£¸é
  • Patellar surface
    ¹«¸­¸é
    [¿¾ ¿ë¾î] ½½°³¸é
  • External surface
    ¹Ù±ù¸é
    [¿¾ ¿ë¾î] ¿Ü¸é
  • Posterior surface of petrous portion
    ¹ÙÀ§µÚ¸é
    [¿¾ ¿ë¾î] ÃßüÈĸé
  • Inferior surface of petrous portion
    ¹ÙÀ§¾Æ·¡¸é
    [¿¾ ¿ë¾î] ÃßüÇϸé
  • Anterior surface of petrous portion
    ¹ÙÀ§¾Õ¸é
    [¿¾ ¿ë¾î] ÃßüÀü¸é
  • Lunate surface
    ¹Ý´Þ¸é
    [¿¾ ¿ë¾î] ¿ù»ó¸é
  • Dorsal surface of toes
    ¹ß°¡¶ôµî
    [¿¾ ¿ë¾î] Á·Áö¹è¸é
  • Plantar surface of toes
    ¹ß°¡¶ô¹Ù´Ú
    [¿¾ ¿ë¾î] Á·Áöô¸é
  • Articular surface for navicular bone
    ¹ß¹è°üÀý¸é
    [¿¾ ¿ë¾î] ÁÖ»ó°ñ°üÀý¸é
  • Thyroid articular surface
    ¹æÆÐ°üÀý¸é
    [¿¾ ¿ë¾î] °©»ó°üÀý¸é
  • Ventral surface
    ¹èÂʸé
    [¿¾ ¿ë¾î] º¹Ãø¸é
  • Sternocostal surface
    º¹Àå°¥ºñ¸é
    [¿¾ ¿ë¾î] Èä´Á¸é
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
¥áHBs Antibody against Hepatitis B surface Antigen
HBsAg Hepatitis B surface Antigen
anti-HBs antibody to hepatitis B surface antigen
HBsAG hepatitis B surface virus
HBS hepatitis B surface [antigen]; hyperkinetic behavior syndrome
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
HBsAg Hepatitis B surface Ag
HBsAb Hepatitis B surface antibody
HBs Hepatitis B surface antigen
anti-HB-s antibodies to hepatitis B surface antigen
HBsAG+ hepatitis B surface antigen positive
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • exposed surface
    ³ëÃâ¸é
  • fatty coating of surface
    Ç¥¸éÀÌ Áö¹æÀ¸·Î µ¤Çô ÀÖ´Â
  • flexor surface
    ±¼°î¸é, ±¼±Ù¸é
  • free surface
    ÀÚÀ¯ ¸é
  • high surface
    °íÇ¥¸é
  • impression of root surface
    ±Ù¸é Àλó
  • impression surface
    Àλó¸é
    ±¸°­ Á¶Á÷ÀÇ ÀÎ»ó¿¡ ÀÇÇØ¼­ °áÁ¤µÈ ÀÇÄ¡ÀÇ Ç¥¸é.
  • inferior surface
    ¾Æ·¡ ¸é
  • inferior surface of tongue
    Çô ¾Æ·¡ ¸é
  • interfacial surface tension
    ÀÇÄ¡ Ç¥¸é Àå·Â
    ÀÇÄ¡ÀÇ Á¢ÇÕµµ°¡ ÁÁÀº °æ¿ì¿¡ À־ ÀÇÄ¡»ó°ú Á¶Á÷°úÀÇ »çÀÌ¿¡ ¾×ü°¡ ¾ãÀº ¸·À¸·Î Çü¼ºµÇ¾î ÀÇÄ¡ÀÇ Å»¶ôÀ» ¹æÁöÇÑ ÀúÇ×·ÂÀÌ´Ù.
  • jugular surface
    °æÁ¤¸Æ Ç¥¸é
  • keratotic surface
    °¢Áú Ç¥¸é
  • labial surface
    ¼ø¸é, ÀüÁ¤¸é
    1. ÀÔ¼ú ÂÊÀ¸·Î ÇâÇÑ ¸é. 2. Ä¡¾ÆÀÇ ÀÔ¼úÃø ¸é.
  • large surface form
    ³ÐÀº ¸éÀÇ ÇüÅÂ
  • laser cavity surface
    ·¹ÀÌÀú Çü¼º ¿Íµ¿¸é
    ·¹ÀÌÀú¸¦ »ç¿ëÇØ Ä¡¾Æ ¿ì½ÄºÎ¸¦ Á¦°ÅÇÏ°í ¿Íµ¿À» Çü¼ºÇÑ ¸é.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
antigens, CD40 <immunology> Differentiation antigens found on all mature B-lymphocytes and some epithelial cells, carcinomas, and lymphoid dendritic cells. This is a member of the tumour necrosis factor superfamily. Evidence suggests that CD40-dependent activation of B-cells is important for generation of memory B-cells within the germinal centres.
(12 Dec 1998)
antigens, CD44 <immunology> Acidic sulfated integral membrane glycoproteins expressed in several alternatively spliced and variable glycosylated forms on a wide variety of cell types including mature T-cells, B-cells, medullary thymocytes, granulocytes, macrophages, erythrocytes, and fibroblasts. Cd44 antigens are the principle cell surface receptors for hyaluronate and this interaction mediates binding of lymphocytes to high endothelial venules.
(12 Dec 1998)
antigens, CD45 <immunology> High-molecular weight glycoproteins uniquely expressed on the surface of all leukocytes and their haemopoietic progenitors. The CD45 family consists of multiple members that are all products of a single gene. Cd45 expression is necessary for signalling through the T-cell receptor.
(12 Dec 1998)
antigens, CD5 <immunology> Glycoproteins expressed on all mature T-cells, thymocytes, and a subset of mature B-cells. Antibodies specific for CD5 can enhance T-cell receptor-mediated T-cell activation. The B-cell-specific molecule CD72 is a natural ligand for CD5.
(12 Dec 1998)
antigens, CD55 <immunology> Glycoproteins broadly distributed among haematopoietic and non-haematopoietic cells. Cd55 prevents the assembly of c3 convertase or accelerates the disassembly of preformed convertase, thus blocking the formation of the membrane attack complex.
(12 Dec 1998)
antigens, CD56 <immunology> The 140-kD isoform of ncam (neural cell adhesion molecule) containing a transmembrane domain and short cytoplasmic tail. It is expressed by all lymphocytes mediating non-MHC restricted cytotoxicity and is present on some neural tissues and tumours.
(12 Dec 1998)
antigens, CD57 <immunology> Oligosaccharide antigenic determinants found principally on nk cells and T-cells. Their role in the immune response is poorly understood.
(12 Dec 1998)
antigens, CD58 <immunology> Glycoproteins with a wide distribution on haematopoietic and non-haematopoietic cells and strongly expressed on macrophages. Cd58 mediates cell adhesion by binding to CD2 (antigens, CD2) and this enhances antigen-specific T-cell activation.
(12 Dec 1998)
antigens, CD59 <immunology> Small glycoproteins found on both haematopoietic and non-haematopoietic cells. Cd59 restricts the cytolytic activity of homologous complement by binding to c8 and c9 and blocking the assembly of the membrane attack complex.
(12 Dec 1998)
antigens, CD7 <immunology> Differentiation antigens expressed on pluripotential haematopoietic cells, most human thymocytes, and a major subset of peripheral blood T-lymphocytes. They have been implicated in integrin-mediated cellular adhesion and as signalling receptors on T-cells.
(12 Dec 1998)
antigens, CD8 <immunology> Differentiation antigens found on thymocytes and on cytotoxic and suppressor T-lymphocytes. Cd8 antigens are members of the immunoglobulin supergene family and are associative recognition elements in major histocompatibility complex class I-restricted interactions.
(12 Dec 1998)
antigens, CD80 <immunology> The natural ligand for the T-cell antigen CD28 (antigens, CD28) mediating t-cell and B-cell adhesion. Cd80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes. The binding of CD80 to CD28 and ctla-4 provides a co-stimulatory signal to T-cells and leads to greatly upregulated lymphokine production.
(12 Dec 1998)
antigens, CD95 <immunology> Differentiation antigens expressed on a variety of cell lines including myeloid and lymphoblastoid cell lines. Their primary role is to regulate peripheral immune responses, which is achieved by triggering apoptosis.
(12 Dec 1998)
antigens, differentiation Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
(12 Dec 1998)
antigens, differentiation, b-lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumours of B-cell origin.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á